# Artelo Biosciences (ARTL) — Earnings

ARTL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/artl/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$151.47 |
| EPS estimate | −$113.13 |
| EPS surprise | −33.89% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 13, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1621221/000164033425001429/artl_10q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 13, 2025 | −$113.13 | −$151.47 | -33.89% | — | — |
| Q1 2025 | May 13, 2025 | −$21.59 | −$116.64 | -440.14% | — | — |
| Q4 2024 | Mar 3, 2025 | −$70.74 | −$189.54 | -167.94% | — | — |
| Q3 2024 | Nov 12, 2024 | −$128.39 | −$56.70 | 55.84% | — | — |
| Q2 2024 | Aug 13, 2024 | −$128.52 | −$121.50 | 5.46% | — | — |
| Q1 2024 | May 13, 2024 | −$158.76 | −$126.36 | 20.41% | — | — |
| Q4 2023 | Mar 25, 2024 | −$90.18 | −$160.38 | -77.84% | — | — |
| Q3 2023 | Nov 13, 2023 | −$104.76 | −$134.46 | -28.35% | — | — |
| Q2 2023 | Aug 10, 2023 | −$125.55 | −$90.72 | 27.74% | — | — |
| Q1 2023 | May 11, 2023 | −$178.20 | −$123.12 | 30.91% | — | — |
| Q3 2022 | Nov 8, 2022 | −$143.10 | −$132.84 | 7.17% | — | — |
| Q2 2022 | Aug 9, 2022 | −$137.70 | −$140.94 | -2.35% | — | — |
| Q1 2022 | May 12, 2022 | −$133.65 | −$194.40 | -45.45% | — | — |
| Q3 2021 | Jul 12, 2021 | −$170.10 | −$243.00 | -42.86% | — | — |
| Q2 2021 | Apr 13, 2021 | −$279.45 | −$267.30 | 4.35% | — | — |
| Q1 2021 | Jan 14, 2021 | −$243.00 | −$340.20 | -40.00% | — | — |
| Q4 2020 | Nov 4, 2020 | −$874.80 | −$534.60 | 38.89% | — | — |
| Q3 2020 | Jul 13, 2020 | −$972.00 | −$656.10 | 32.50% | — | — |

## Frequently Asked Questions

### When did Artelo Biosciences (ARTL) last report earnings?

Artelo Biosciences last reported on Aug 13, 2025, covering fiscal Q2 2025.

### Did ARTL beat earnings estimates?

No. Artelo Biosciences reported EPS of −$151.47 for Q2 2025 against a −$113.13 estimate — a 33.89% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).